临床阶段制药公司Allarity Therapeutics近日与一家未公开名称的欧盟生物技术企业达成新的商业协议。根据协议条款，合作方将获得非独家全球授权，可在乳腺癌领域应用Allarity专有的DRP®算法技术，并能够使用该公司丹麦医学实验室的服务资源。
此次战略合作将助力合作方提升精准肿瘤诊疗解决方案的技术能力。协议包含未来十二个月内对Allarity实验室服务的购买承诺，尽管预计不会显著改变Allarity当前的财务前景，但凸显了其DRP®平台在预测肿瘤反应及改善治疗效果方面的应用价值正获得业界认可。
DRP®技术平台通过算法模型分析肿瘤生物标志物，为个体化治疗方案提供科学依据。本次协议拓展了该技术在乳腺癌诊断领域的商业化路径，标志着平台技术输出取得实质性进展。
免责声明：本文内容不构成任何投资建议，相关信息请以公司公告为准。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.